TY  - GEN
AU  - Shi,Yuankai
AU  - Su,Hang
AU  - Song,Yongping
AU  - Jiang,Wenqi
AU  - Sun,Xiuhua
AU  - Qian,Wenbin
AU  - Zhang,Wei
AU  - Gao,Yuhuan
AU  - Jin,Zhengming
AU  - Zhou,Jianfeng
AU  - Jin,Chuan
AU  - Zou,Liqun
AU  - Qiu,Lugui
AU  - Li,Wei
AU  - Yang,Jianmin
AU  - Hou,Ming
AU  - Xiong,Yan
AU  - Zhou,Hui
AU  - Du,Xinhua
AU  - Wang,Xiong
AU  - Peng,Bo
TI  - Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
SN  - 2352-3964
PY  - 2021///0125
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Circulating Tumor DNA
KW  - DNA-Binding Proteins
KW  - Drug Resistance, Neoplasm
KW  - F-Box Proteins
KW  - Female
KW  - Hodgkin Disease
KW  - blood
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Jumonji Domain-Containing Histone Demethylases
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Receptors, Tumor Necrosis Factor, Member 14
KW  - Transcription Factors
KW  - beta 2-Microglobulin
N1  - Publication Type: Clinical Trial; Journal Article
UR  - https://doi.org/10.1016/j.ebiom.2020.102731
ER  -